Table 1.
Vaccine responses
| Healthy control | Leukemia | Lymphoma | Multiple myeloma | All patients | ||
|---|---|---|---|---|---|---|
| Total individuals | 69 | 157 | 173 | 221 | 551 | |
| Vaccine subtype | BNT162b2 | 58 (84.1%) | 105 | 136 | 172 | 413 (75%) |
| mRNA-1273 | 11 (15.9%) | 52 | 37 | 49 | 138 (25%) | |
| SARS-CoV-2 spike IgG antibody response: Prior COVID-19 illness | 1 mo seropositive rate | 8/9 (88.9%) | 1/1 (100%) | 5/5 (100%) | 6/6 (100%) | 12/12 (100%) |
| 1 mo Ab titer (AU/mL): mean ± SD | 16,881 ± 8,302 | 719.9 ± 0 | 13,748 ± 11,792 | 21,881 ± 4,984 | 16,729 ± 10,182 | |
| 1 mo Ab titer (AU/mL): median (IQR) | 16,850 (12,763–24,672) | 719.9 (719.9–719.9) | 15,536 (1,602–25,000) | 25,000 (16,607–25,000) | 21,286 (5,787–25,000) | |
| 3 mo seropositive rate | 9/9 (100%) | 5/7 (71.4%) | 10/10 (100%) | 10/11 (90.9%) | 25/28 (89.3%) | |
| 3 mo Ab titer (AU/mL): mean ± SD | 17,737 ± 6,327 | 14,617 ± 12,973 | 19,003 ± 9,006 | 17,817 ± 8,492 | 17,441 ± 9,704 | |
| 3 mo Ab titer (AU/mL): median (IQR) | 16,748 (11,566–25,000) | 25,000 (4.9–25,000) | 24,798 (12,669–25,000) | 21,749 (11,244–25,000) | 24,798 (10,604–25,000) | |
| SARS-CoV-2 spike IgG antibody response: No prior COVID-19 illness | 1 mo seropositive rate | 59/59 (100%) | 10/34 (29.4%) | 18/38 (47.4%) | 58/95 (61.1%) | 86/167 (51.5%) |
| 1 mo Ab titer (AU/mL): mean ± SD | 2,620 ± 5,104 | 1,137 ± 4,598 | 1,481 ± 4,015 | 1,716 ± 4,889 | 1,545 ± 4,624 | |
| 1 mo Ab titer (AU/mL): median (IQR) | 886.2 (502.3–2,240) | 4.5 (1.8–86.33) | 46 (4.9–329.9) | 96.6 (8.3–571.4) | 55.7 (4–465.7) | |
| 3 mo seropositive rate | 54/54 (100%) | 73/131 (55.7%) | 74/132 (56.1%) | 167/193 (86.5%) | 314/456 (68.9%) | |
| 3 mo Ab titer (AU/mL): mean ± SD | 7,656 ± 4,701 | 3,827 ± 7,217 | 4,241 ± 7,752 | 4,176 ± 6,775 | 4,095 ± 7,182 | |
| 3 mo Ab titer (AU/mL): median (IQR) | 7,720 (3,885–9,746) | 187 (5–3,632) | 127 (6.5–3,592) | 1,218 (180.4–4,424) | 517.7 (18.2–3,779) |
| Healthy control | Patients with hematologic malignancies | |||||
|---|---|---|---|---|---|---|
| Neutralizing antibody | 1 mo positive inhibition | 55/59 (93.2%) | 21/80 (26.3%) | |||
| 1 mo: mean % inhibition ± SD | 62.8 ± 20.3 | 22.8 ± 26.3 | ||||
| 1 mo: median % inhibition (IQR) | 63.6 (51.3–78.4) | 11.3 (4.9–30.6) | ||||
| 3 mo positive inhibition | 21/21 (100%) | 17/39 (43.6%) | ||||
| 3 mo: mean % inhibition ± SD | 94 ± 4.2 | 36 ± 40.4 | ||||
| 3 mo: median % inhibition (IQR) | 95.6 (93.8–95.9) | 9.3 (1–86.7) | ||||
Abbreviations: Ab, antibody; AU/mL, artificial units/milliliter; IQR, interquartile range; mo, month; SD, standard deviation.